Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan approves AstraZeneca Faslodex 500mg
Faslodex is an oestrogen receptor antagonist, which can bind, block and degrade the oestrogen receptor, thereby helping in the treatment of hormone receptor-positive metastatic breast cancer which has
Faslodex is an oestrogen receptor antagonist, which can bind, block and degrade the oestrogen receptor, thereby helping in the treatment of hormone receptor-positive metastatic breast cancer which has
The study , which was conducted between 2004 and 2009, evaluated the efficiency of isolated soy protein consumption on the progression of atherosclerosis. The double-blind, placebo-controlled parallel-design study
Single-tablet regimen, Eviplera, combines Gilead’s Truvada (emtricitabine and tenofovir disoproxil (as fumarate)) with Tibotec Pharmaceuticals’ non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine (as hydrochloride)). The submission of the application
The patent protects Invisicare in three main areas: its composition, its method of combining polymers to make the Invisicare complex and the skin / medical conditions Invisicare is
The Phase 1 dose-ranging study expects to investigate ACY-1215 alone and in conjunction with bortezomib (Velcade) and dexamethasone. Following identification of optimal combination dosing in Phase 1, the
Fibroblast Growth Factor 21 (FGF-21) protein is indicated for use in treating type 2 diabetes, and the Relaxin hormone, for treating heart failure. The agreement enables Ambrx to
The company’s Rivastigmine Tartrate Capsules are the generic version of Novartis’ Exelon Capsules. Exelon is a cholinesterase inhibitor which helps in treating mild to moderate dementia in patients
The lawsuit alleges that under an agreement signed with Watson Pharmaceuticals, Amphastar has given right to market, sell and distribute Enoxaparin Sodium Injection in the US, infringing Momenta’s
Developed by ImmunoGen, IMGN529 is indicated as a treatment for B-cell malignancies including non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). ImmunoGen president and CEO Daniel Junius said
The 52-week analysis showed that saxagliptin tablet added to insulin (with or without metformin) reduced blood sugar levels (HbA1c) in adult patients with type 2 diabetes compared to